These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2392216)

  • 1. The effect of long-term physostigmine administration in Alzheimer's disease.
    Harrell LE; Callaway R; Morere D; Falgout J
    Neurology; 1990 Sep; 40(9):1350-4. PubMed ID: 2392216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological and neuropsychological characterization of physostigmine responders and nonresponders in Alzheimer's disease.
    Harrell LE; Jope RS; Falgout J; Callaway R; Avery C; Spiers M; Leli D; Morere D; Halsey JH
    J Am Geriatr Soc; 1990 Feb; 38(2):113-22. PubMed ID: 2405043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term administration of oral physostigmine in Alzheimer's disease.
    Stern Y; Sano M; Mayeux R
    Neurology; 1988 Dec; 38(12):1837-41. PubMed ID: 3057398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial.
    Jenike MA; Albert MS; Heller H; Gunther J; Goff D
    J Clin Psychiatry; 1990 Jan; 51(1):3-7. PubMed ID: 2403997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of oral physostigmine in Alzheimer's disease.
    Stern Y; Sano M; Mayeux R
    Ann Neurol; 1987 Sep; 22(3):306-10. PubMed ID: 3674795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral physostigmine as treatment for primary degenerative dementia: a double-blind placebo-controlled inpatient trial.
    Jenike MA; Albert M; Baer L; Gunther J
    J Geriatr Psychiatry Neurol; 1990; 3(1):13-6. PubMed ID: 2189429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physostigmine effects in Alzheimer's disease: relationship to dementia severity.
    Schwartz AS; Kohlstaedt EV
    Life Sci; 1986 Mar; 38(11):1021-8. PubMed ID: 3512944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral physostigmine treatment of patients with Alzheimer's disease.
    Mohs RC; Davis BM; Johns CA; Mathé AA; Greenwald BS; Horvath TB; Davis KL
    Am J Psychiatry; 1985 Jan; 142(1):28-33. PubMed ID: 3881051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of clinical efficacy of chronic oral physostigmine in Alzheimer's disease.
    Jotkowitz S
    Ann Neurol; 1983 Dec; 14(6):690-1. PubMed ID: 6360031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of physostigmine on constructional and memory tasks in Alzheimer's disease.
    Muramoto O; Sugishita M; Sugita H; Toyokura Y
    Arch Neurol; 1979 Aug; 36(8):501-3. PubMed ID: 508162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A strategy of "combination chemotherapy" in Alzheimer's disease: rationale and preliminary results with physostigmine plus deprenyl.
    Sunderland T; Molchan S; Lawlor B; Martinez R; Mellow A; Martinson H; Putnam K; Lalonde F
    Int Psychogeriatr; 1992; 4 Suppl 2():291-309. PubMed ID: 1288668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Memory enhancement with oral physostigmine in Alzheimer's disease.
    N Engl J Med; 1983 Mar; 308(12):720-1. PubMed ID: 6338388
    [No Abstract]   [Full Text] [Related]  

  • 13. Physostigmine and tetrahydroaminoacridine treatment of Alzheimer's disease.
    Gustafson L
    Acta Neurol Scand Suppl; 1993; 149(Rand):39-41. PubMed ID: 8128836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease.
    Thal LJ; Ferguson JM; Mintzer J; Raskin A; Targum SD
    Neurology; 1999 Apr; 52(6):1146-52. PubMed ID: 10214735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease.
    Asthana S; Greig NH; Hegedus L; Holloway HH; Raffaele KC; Schapiro MB; Soncrant TT
    Clin Pharmacol Ther; 1995 Sep; 58(3):299-309. PubMed ID: 7554703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical studies of the cholinergic deficit in Alzheimer's disease. II. Psychopharmacologic studies.
    Mohs RC; Davis BM; Greenwald BS; Mathé AA; Johns CA; Horvath TB; Davis KL
    J Am Geriatr Soc; 1985 Nov; 33(11):749-57. PubMed ID: 2865282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease.
    Thal LJ; Masur DM; Blau AD; Fuld PA; Klauber MR
    J Am Geriatr Soc; 1989 Jan; 37(1):42-8. PubMed ID: 2642499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transdermal physostigmine in the treatment of Alzheimer's disease.
    Levy A; Brandeis R; Treves TA; Meshulam Y; Mawassi F; Feiler D; Wengier A; Glikfeld P; Grunwald J; Dachir S
    Alzheimer Dis Assoc Disord; 1994; 8(1):15-21. PubMed ID: 8185877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group.
    Thal LJ; Schwartz G; Sano M; Weiner M; Knopman D; Harrell L; Bodenheimer S; Rossor M; Philpot M; Schor J; Goldberg A
    Neurology; 1996 Dec; 47(6):1389-95. PubMed ID: 8960716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physostigmine in Alzheimer's disease.
    Smith CM; Swash M
    Lancet; 1979 Jan; 1(8106):42. PubMed ID: 83485
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.